Effects of delafloxacin injection: A Synthesis of Findings from 4 Studies

  1. Home
  2. Effects of delafloxacin injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of delafloxacin injection: A Synthesis of Findings from 4 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of delafloxacin injection: A Synthesis of Findings from 4 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Delafloxacin, a new fluoroquinolone (FQ), has shown promise as a treatment for acute bacterial skin and skin structure infections (ABSSSIs), particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). 4 It has a unique chemical structure that enhances its antibacterial activity in acidic environments, which is common in ABSSSIs. 4 Clinical trials have demonstrated that intravenous delafloxacin is noninferior to vancomycin plus aztreonam in treating ABSSSIs. 4 Furthermore, single-dose oral delafloxacin has proven effective in treating uncomplicated gonorrhea. 3 In the context of HIV infection, ritonavir-boosted atazanavir and darunavir have emerged as preferred protease inhibitors for initial treatment due to their superior lipid effects and overall tolerability compared to ritonavir-boosted lopinavir. 2 Darunavir/ritonavir has also demonstrated noninferiority to lopinavir/ritonavir in treatment-naive patients, particularly those with high viral loads. 1

Benefits and Risks

Benefit Summary

Delafloxacin exhibits a broad spectrum of activity against clinically relevant Gram-positive and Gram-negative pathogens, including MRSA. 4 It has proven effective in treating ABSSSIs and uncomplicated gonorrhea, offering a potential alternative to existing antibiotics. 4 3 Darunavir/ritonavir demonstrates favorable lipid effects and overall tolerability in the initial treatment of HIV infection, potentially providing a more well-tolerated option compared to other protease inhibitors. 2 It is particularly effective in patients with high viral loads. 1

Risk Summary

While generally well-tolerated, delafloxacin carries the risk of fluoroquinolone-associated adverse events, such as tendon rupture and QT prolongation. 4 Darunavir/ritonavir can lead to lipid abnormalities. 2

Comparison of Studies

Similarities

These studies all involved clinical trials to evaluate the efficacy of antibiotics or antiretroviral medications. 4 3 2 1

Differences

The studies focused on different diseases and medications. 4 3 2 1 They also employed diverse study designs and assessed different endpoints. 4 3 2 1

Consistency and Inconsistencies of Results

While the studies suggest potential benefits of delafloxacin and darunavir/ritonavir, they do not all reach identical conclusions. 4 3 2 1 Direct comparisons of the results can be challenging due to the differences in diseases and medications investigated. 4 3 2 1

Considerations for Real-World Application

Delafloxacin appears to be a viable treatment option for ABSSSIs, offering a potential alternative to existing antibiotics. 4 However, it's crucial to be aware of the associated risks of fluoroquinolones, such as tendon rupture and QT prolongation. 4 Darunavir/ritonavir presents a promising option for the initial treatment of HIV infection, particularly for patients with high viral loads. 2 1 However, the risk of lipid abnormalities should be considered. 2 It's essential to follow the guidance of healthcare professionals when using these medications. 4 2

Limitations of Current Research

These studies are limited to specific diseases and medications, making generalizations difficult. 4 3 2 1 Furthermore, the studies are relatively small, necessitating further confirmation of the findings. 4 3 2 1

Future Research Directions

Further research is necessary to evaluate the long-term efficacy and safety of these medications. 4 2 Additionally, comparative studies against other drugs are needed to better understand their relative efficacy. 4 2

Conclusion

Delafloxacin and darunavir/ritonavir hold potential as promising therapeutic options for ABSSSIs and HIV infection, respectively. 4 2 It's essential to follow healthcare professional guidance when using these medications. 4 2 Further research is anticipated to provide more comprehensive information on the efficacy and safety of these agents. 4 2

Literature analysis of 4 papers
Positive Content
4
Neutral Content
0
Negative Content
0
Article Type
3
0
0
1
4
1.

[Darunavir in treatment-naïve patients. The ARTEMIS study].

Author: EstradaVicente, FusterMónica

HIV treatment efficacy
Increased CD4 count
Reduced adverse effects

The ARTEMIS study compared the effectiveness of darunavir/ritonavir and lopinavir/ritonavir for treating HIV in people who had never taken HIV medications before. Both medications were effective, but darunavir/ritonavir was more effective in patients with higher levels of HIV in their blood. Darunavir/ritonavir also had fewer side effects, particularly digestive problems and changes in lipid levels.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : Spanish

2.

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.

Author: MartinezE, Gonzalez-CordonA, FerrerE, DomingoP, NegredoE, GutierrezF, PortillaJ, CurranA, PodzamczerD, MurillasJ, BernardinoJ I, SantosI, CartonJ A, PeraireJ, PichJ, PerezI, GatellJ M,

Lipid effects
Tolerability
Hyperbilirubinaemia

This study examines the lipid effects and overall tolerability of ritonavir-boosted atazanavir and darunavir compared to ritonavir-boosted lopinavir in patients with HIV infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study.

Author: HookEdward W, GoldenMatthew R, TaylorStephanie N, HenryEugenia, TsengCarol, WorkowskiKimberly A, SwerdlowJerri, NenningerAshley, CammarataSue

Gonorrhea treatment

This study evaluated the efficacy and safety of delafloxacin, a new fluoroquinolone antibiotic, compared to ceftriaxone for the treatment of uncomplicated urogenital gonorrhea. The study found that both delafloxacin and ceftriaxone were effective in treating uncomplicated urogenital gonorrhea.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Author: ScottL J

ABSSSI treatment

Delafloxacin, a new fluoroquinolone (FQ), has been shown to be non-inferior to intravenous vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Delafloxacin was well-tolerated with few treatment-related adverse events. Intravenous delafloxacin offers a novel option for the treatment of adult patients with ABSSSIs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.